prasterone
Term · Oncology and biomedicine · MLC-T-ONC-016207
A synthetic form of dehydroepiandrosterone with potential chemopreventive activity. Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens. Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities.
| Identifier | MLC-T-ONC-016207 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | DHEA |
| Synonyms | therapeutic dehydroepiandrosterone; Dehydroisoandrosterone |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016207",
"term": "prasterone",
"field": "Oncology and biomedicine",
"definition": "A synthetic form of dehydroepiandrosterone with potential chemopreventive activity. Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens. Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities.",
"abbreviation": "DHEA",
"synonyms": [
"therapeutic dehydroepiandrosterone",
"Dehydroisoandrosterone"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/prasterone/"
}
Record 13,564 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.